Iovance Biotherapeutics (IOVA) Competitors $3.62 -0.02 (-0.41%) As of 01:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IOVA vs. PTCT, RNA, ACLX, OGN, ZLAB, SWTX, RARE, AKRO, ALVO, and RYTMShould you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include PTC Therapeutics (PTCT), Avidity Biosciences (RNA), Arcellx (ACLX), Organon & Co. (OGN), Zai Lab (ZLAB), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), Alvotech (ALVO), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Iovance Biotherapeutics vs. PTC Therapeutics Avidity Biosciences Arcellx Organon & Co. Zai Lab SpringWorks Therapeutics Ultragenyx Pharmaceutical Akero Therapeutics Alvotech Rhythm Pharmaceuticals PTC Therapeutics (NASDAQ:PTCT) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings, community ranking and profitability. Is PTCT or IOVA more profitable? PTC Therapeutics has a net margin of -50.32% compared to Iovance Biotherapeutics' net margin of -451.25%. PTC Therapeutics' return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics-50.32% N/A -16.44% Iovance Biotherapeutics -451.25%-58.43%-45.48% Does the media refer more to PTCT or IOVA? In the previous week, Iovance Biotherapeutics had 8 more articles in the media than PTC Therapeutics. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 9 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 1.10 beat Iovance Biotherapeutics' score of 0.44 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more risk & volatility, PTCT or IOVA? PTC Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Do analysts recommend PTCT or IOVA? PTC Therapeutics currently has a consensus price target of $64.00, indicating a potential upside of 19.38%. Iovance Biotherapeutics has a consensus price target of $20.25, indicating a potential upside of 460.17%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 2 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.53Iovance Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Which has better valuation & earnings, PTCT or IOVA? Iovance Biotherapeutics has lower revenue, but higher earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M5.24-$626.60M-$4.73-11.33Iovance Biotherapeutics$164.07M7.22-$444.04M-$1.30-2.78 Do institutionals & insiders have more ownership in PTCT or IOVA? 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by insiders. Comparatively, 12.1% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in PTCT or IOVA? Iovance Biotherapeutics received 2 more outperform votes than PTC Therapeutics when rated by MarketBeat users. Likewise, 74.41% of users gave Iovance Biotherapeutics an outperform vote while only 61.87% of users gave PTC Therapeutics an outperform vote. CompanyUnderperformOutperformPTC TherapeuticsOutperform Votes56861.87% Underperform Votes35038.13% Iovance BiotherapeuticsOutperform Votes57074.41% Underperform Votes19625.59% SummaryIovance Biotherapeutics beats PTC Therapeutics on 12 of the 19 factors compared between the two stocks. Remove Ads Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOVA vs. The Competition Export to ExcelMetricIovance BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$3.03B$5.64B$7.85BDividend YieldN/A1.56%4.57%4.01%P/E Ratio-2.4328.9823.1418.69Price / Sales7.22427.21389.3791.52Price / CashN/A168.6838.1634.64Price / Book1.593.916.894.24Net Income-$444.04M-$71.95M$3.20B$247.06M7 Day Performance2.12%-5.52%-2.61%-1.91%1 Month Performance-14.74%-11.94%1.89%-5.51%1 Year Performance-75.61%-28.29%9.97%-0.57% Iovance Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOVAIovance Biotherapeutics4.3199 of 5 stars$3.62-0.4%$20.25+460.2%-74.3%$1.19B$164.07M-2.43500PTCTPTC Therapeutics3.4714 of 5 stars$57.11-0.1%$64.00+12.1%+86.8%$4.50B$806.78M-9.611,410Positive NewsRNAAvidity Biosciences2.3139 of 5 stars$33.54+8.7%$66.69+98.9%+32.0%$4.03B$10.90M-11.64190ACLXArcellx2.2486 of 5 stars$72.19+4.1%$108.46+50.3%-2.8%$3.97B$107.94M-101.8080Positive NewsOGNOrganon & Co.4.7795 of 5 stars$15.37-0.2%$20.80+35.4%-21.1%$3.96B$6.40B4.6110,000News CoveragePositive NewsZLABZai Lab2.4228 of 5 stars$35.40+0.9%$47.37+33.8%+123.5%$3.88B$398.99M-12.781,950Analyst ForecastPositive NewsGap UpSWTXSpringWorks Therapeutics2.3806 of 5 stars$49.17-1.4%$73.20+48.9%-5.2%$3.74B$191.59M-14.13230Positive NewsRAREUltragenyx Pharmaceutical4.4361 of 5 stars$39.45+0.7%$91.71+132.5%-16.9%$3.65B$560.23M-6.221,276Analyst ForecastNews CoveragePositive NewsAKROAkero Therapeutics4.2598 of 5 stars$44.94-0.6%$76.29+69.7%+78.2%$3.58BN/A-11.9830Insider TradePositive NewsGap UpALVOAlvotech2.006 of 5 stars$11.59+0.2%$18.00+55.3%-18.3%$3.48B$391.87M-6.241,026Earnings ReportNews CoverageRYTMRhythm Pharmaceuticals4.4334 of 5 stars$53.63+3.0%$69.46+29.5%+28.0%$3.39B$130.13M-12.38140Analyst Revision Remove Ads Related Companies and Tools Related Companies PTC Therapeutics Competitors Avidity Biosciences Competitors Arcellx Competitors Organon & Co. Competitors Zai Lab Competitors SpringWorks Therapeutics Competitors Ultragenyx Pharmaceutical Competitors Akero Therapeutics Competitors Alvotech Competitors Rhythm Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOVA) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
